Does the media favor ROIV or REGN?

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Regeneron Pharmaceuticals' score of 0.56 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ARGX or ROIV?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.58 $1.29B $26.04 38.03 Roivant Sciences $8.26M 3,477.80 -$299.77M -$0.53 N/A

Is ARGX or ROIV more profitable?

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media favor ARGX or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than argenex. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for argenex. Roivant Sciences' average media sentiment score of 0.85 beat argenex's score of 0.30 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ROIV or MRNA more profitable?

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Moderna -141.43% -28.30% -19.39%

Does the media prefer ROIV or MRNA?

In the previous week, Moderna had 24 more articles in the media than Roivant Sciences. MarketBeat recorded 33 mentions for Moderna and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Moderna's score of 0.40 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ROIV or NTRA?

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,477.80 -$299.77M -$0.53 N/A Natera $2.71B 19.67 -$208.16M -$1.36 N/A

Is ROIV or NTRA more profitable?

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Natera -7.11% -11.38% -7.87%

Does the media prefer ROIV or NTRA?

In the previous week, Natera had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Natera and 9 mentions for Roivant Sciences. Natera's average media sentiment score of 0.91 beat Roivant Sciences' score of 0.85 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or RVMD?

In the previous week, Revolution Medicines had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 24 mentions for Revolution Medicines and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Revolution Medicines' score of 0.57 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Roivant Sciences (ROIV) Competitors

$39.77 -0.21 (-0.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.33 +0.56 (+1.40%)

As of 09/18/2026 07:30 PM Eastern

Compare

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Roivant Sciences stock or one of its competitors? Roivant Sciences's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Roivant Sciences (NASDAQ:ROIV) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Roivant Sciences currently has a consensus price target of $45.64, suggesting a potential upside of 14.75%. Regeneron Pharmaceuticals has a consensus price target of $802.18, suggesting a potential upside of 2.21%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Regeneron Pharmaceuticals	$14.34B	5.63	$4.50B	$40.46	19.40

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Roivant Sciences' net margin of -3,534.96%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Regeneron Pharmaceuticals' score of 0.56 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Regeneron Pharmaceuticals beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to argenex?

argenex (NASDAQ:ARGX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

argenex currently has a consensus price target of $1,158.61, indicating a potential upside of 16.99%. Roivant Sciences has a consensus price target of $45.64, indicating a potential upside of 14.75%. Given argenex's stronger consensus rating and higher probable upside, research analysts clearly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Roivant Sciences had 3 more articles in the media than argenex. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for argenex. Roivant Sciences' average media sentiment score of 0.85 beat argenex's score of 0.30 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.58	$1.29B	$26.04	38.03
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A

60.3% of argenex shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

argenex beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Moderna?

Roivant Sciences (NASDAQ:ROIV) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Roivant Sciences has higher earnings, but lower revenue than Moderna. Roivant Sciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A

Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

In the previous week, Moderna had 24 more articles in the media than Roivant Sciences. MarketBeat recorded 33 mentions for Moderna and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Moderna's score of 0.40 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Moderna has a net margin of -141.43% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Moderna	-141.43%	-28.30%	-19.39%

Roivant Sciences currently has a consensus price target of $45.64, indicating a potential upside of 14.75%. Moderna has a consensus price target of $76.72, indicating a potential downside of 50.19%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Roivant Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Roivant Sciences beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Natera?

Roivant Sciences (NASDAQ:ROIV) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Natera had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Natera and 9 mentions for Roivant Sciences. Natera's average media sentiment score of 0.91 beat Roivant Sciences' score of 0.85 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.38% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Natera	-7.11%	-11.38%	-7.87%

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Natera has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Natera	$2.71B	19.67	-$208.16M	-$1.36	N/A

Roivant Sciences currently has a consensus target price of $45.64, indicating a potential upside of 14.75%. Natera has a consensus target price of $330.83, indicating a potential downside of 10.44%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Roivant Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Natera beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Roivant Sciences (NASDAQ:ROIV) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Revolution Medicines had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 24 mentions for Revolution Medicines and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Revolution Medicines' score of 0.57 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Roivant Sciences presently has a consensus target price of $45.64, indicating a potential upside of 14.75%. Revolution Medicines has a consensus target price of $226.17, indicating a potential upside of 18.44%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Revolution Medicines	N/A	-88.20%	-57.85%

Roivant Sciences has higher earnings, but lower revenue than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A

Summary

Revolution Medicines beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.88B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-75.04	14.08	273.81	25.39
Price / Sales	3,477.80	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	5.41	15.45	10.45	6.33
Net Income	-$299.77M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-2.57%	-1.22%	0.88%	1.17%
1 Month Performance	6.34%	-4.44%	-1.59%	-2.59%
1 Year Performance	164.43%	37.78%	18.08%	5.97%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	2.8404 of 5 stars	$39.77 -0.5%	$45.64 +14.8%	+163.6%	$28.88B	$8.26M	N/A	721	Analyst Forecast Insider Trade High Trading Volume
REGN Regeneron Pharmaceuticals	3.7817 of 5 stars	$793.74 +1.6%	$802.18 +1.1%	+31.1%	$80.46B	$14.34B	19.62	15,410
ARGX argenex	4.4836 of 5 stars	$990.54 +0.6%	$1,158.61 +17.0%	+35.3%	$61.58B	$4.25B	38.04	1,863	News Coverage Analyst Downgrade Gap Up
MRNA Moderna	2.1613 of 5 stars	$146.69 +1.9%	$76.72 -47.7%	+505.2%	$57.48B	$2.21B	N/A	4,700	Trending News Insider Trade
NTRA Natera	1.7938 of 5 stars	$341.79 +3.9%	$330.83 -3.2%	+105.4%	$47.41B	$2.31B	N/A	6,140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Moderna?

Summary

How does Roivant Sciences compare to Natera?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Do analysts rate ROIV or REGN?

Do institutionals and insiders hold more shares of ROIV or REGN?

Which has more risk & volatility, ROIV or REGN?

Which has stronger valuation & earnings, ROIV or REGN?

Is ROIV or REGN more profitable?

Does the media favor ROIV or REGN?

Summary

How does Roivant Sciences compare to argenex?

Do analysts recommend ARGX or ROIV?

Which has more risk & volatility, ARGX or ROIV?

Does the media favor ARGX or ROIV?

Is ARGX or ROIV more profitable?

Which has stronger earnings & valuation, ARGX or ROIV?

Do insiders and institutionals believe in ARGX or ROIV?

Summary

How does Roivant Sciences compare to Moderna?

Which has stronger valuation & earnings, ROIV or MRNA?

Which has more risk and volatility, ROIV or MRNA?

Does the media prefer ROIV or MRNA?

Is ROIV or MRNA more profitable?

Do analysts recommend ROIV or MRNA?

Do institutionals & insiders believe in ROIV or MRNA?

Summary

How does Roivant Sciences compare to Natera?

Do insiders and institutionals have more ownership in ROIV or NTRA?

Does the media prefer ROIV or NTRA?

Is ROIV or NTRA more profitable?

Which has more risk and volatility, ROIV or NTRA?

Which has stronger earnings and valuation, ROIV or NTRA?

Do analysts rate ROIV or NTRA?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Do insiders & institutionals believe in ROIV or RVMD?

Does the media favor ROIV or RVMD?

Which has more risk and volatility, ROIV or RVMD?

Do analysts prefer ROIV or RVMD?

Is ROIV or RVMD more profitable?

Which has preferable earnings & valuation, ROIV or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools